{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T18:44:52Z","timestamp":1793385892044,"version":"4.5.0"},"reference-count":47,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2017,11,21]],"date-time":"2017-11-21T00:00:00Z","timestamp":1511222400000},"content-version":"vor","delay-in-days":1,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,1]]},"DOI":"10.1093\/jnci\/djx236","type":"journal-article","created":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T15:11:33Z","timestamp":1508253093000},"page":"467-478","source":"Crossref","is-referenced-by-count":99,"title":["Targeting BCR-ABL-Independent TKI Resistance in Chronic Myeloid Leukemia by mTOR and Autophagy Inhibition"],"prefix":"10.1093","volume":"110","author":[{"given":"Rebecca","family":"Mitchell","sequence":"first","affiliation":[{"name":"Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa E M","family":"Hopcroft","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo","family":"Baquero","sequence":"additional","affiliation":[{"name":"Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine K","family":"Allan","sequence":"additional","affiliation":[{"name":"Scottish National Blood Transfusion Service, Gartnavel General Hospital, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay","family":"Hewit","sequence":"additional","affiliation":[{"name":"Cancer Research UK, Beatson Institute, Garscube Estate, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"James","sequence":"additional","affiliation":[{"name":"Cancer Research UK, Beatson Institute, Garscube Estate, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Graham","family":"Hamilton","sequence":"additional","affiliation":[{"name":"Glasgow Polyomics, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arunima","family":"Mukhopadhyay","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jim","family":"O\u2019Prey","sequence":"additional","affiliation":[{"name":"Cancer Research UK, Beatson Institute, Garscube Estate, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Hair","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junia V","family":"Melo","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia and Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edmond","family":"Chan","sequence":"additional","affiliation":[{"name":"Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M","family":"Ryan","sequence":"additional","affiliation":[{"name":"Cancer Research UK, Beatson Institute, Garscube Estate, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V\u00e9ronique","family":"Maguer-Satta","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique 1G, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J","family":"Druker","sequence":"additional","affiliation":[{"name":"Division of Hematology and Medical Oncology, Oregon Health and Science University, Knight Cancer Institute, Portland, OR"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E","family":"Clark","sequence":"additional","affiliation":[{"name":"Institute of Translational Medicine, Department of Molecular and Clinical Cancer Medicine, University of Liverpool, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subir","family":"Mitra","sequence":"additional","affiliation":[{"name":"Department of Haematology, Milton Keynes Hospital NHS Foundation Trust, Milton Keynes, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pawel","family":"Herzyk","sequence":"additional","affiliation":[{"name":"Glasgow Polyomics, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"},{"name":"Institute of Molecular, Cell and Systems Biology, College of Medical, Veterinary and Life Sciences, University of Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franck E","family":"Nicolini","sequence":"additional","affiliation":[{"name":"H\u00e9matologie Clinique 1G, Centre Hospitalier Lyon Sud, Pierre B\u00e9nite, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Salomoni","sequence":"additional","affiliation":[{"name":"Samantha Dickson Brain Cancer Unit, UCL Cancer Institute, Paul O'Gorman Building, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Shanks","sequence":"additional","affiliation":[{"name":"Faculty of Health and Medical Sciences, University of Adelaide, Adelaide, Australia and Imperial College, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Calabretta","sequence":"additional","affiliation":[{"name":"Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tessa L","family":"Holyoake","sequence":"additional","affiliation":[{"name":"Paul O\u2019Gorman Leukaemia Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G Vignir","family":"Helgason","sequence":"additional","affiliation":[{"name":"Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2017,11,20]]},"reference":[{"issue":"5405","key":"key\n\t\t\t\t20180510195532_djx236-B1","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1038\/243290a0","article-title":"Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining","volume":"243","author":"Rowley","year":"1973","journal-title":"Nature"},{"issue":"4944","key":"key\n\t\t\t\t20180510195532_djx236-B2","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1126\/science.2406902","article-title":"Induction of chronic myelogenous leukemia in mice by the P210bcr\/abl gene of the Philadelphia chromosome","volume":"247","author":"Daley","year":"1990","journal-title":"Science."},{"issue":"23","key":"key\n\t\t\t\t20180510195532_djx236-B3","doi-asserted-by":"crossref","first-page":"2408","DOI":"10.1056\/NEJMoa062867","article-title":"Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia","volume":"355","author":"Druker","year":"2006","journal-title":"N Engl J Med."},{"issue":"1","key":"key\n\t\t\t\t20180510195532_djx236-B4","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1182\/blood.V99.1.319","article-title":"Primitive, quiescent, Philadelphia-positive stem cells from patients with chronic myeloid leukemia are insensitive to STI571 in vitro","volume":"99","author":"Graham","year":"2002","journal-title":"Blood."},{"issue":"1","key":"key\n\t\t\t\t20180510195532_djx236-B5","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1172\/JCI35721","article-title":"Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity","volume":"121","author":"Corbin","year":"2011","journal-title":"J Clin Invest."},{"issue":"11","key":"key\n\t\t\t\t20180510195532_djx236-B6","doi-asserted-by":"crossref","first-page":"4532","DOI":"10.1182\/blood-2005-07-2947","article-title":"Dasatinib (BMS-354825) targets an earlier progenitor population than imatinib in primary CML but does not eliminate the quiescent fraction","volume":"107","author":"Copland","year":"2006","journal-title":"Blood."},{"issue":"6","key":"key\n\t\t\t\t20180510195532_djx236-B7","doi-asserted-by":"crossref","first-page":"1501","DOI":"10.1182\/blood-2010-12-326843","article-title":"Chronic myeloid leukemia stem cells are not dependent on Bcr-Abl kinase activity for their survival","volume":"119","author":"Hamilton","year":"2012","journal-title":"Blood."},{"issue":"1","key":"key\n\t\t\t\t20180510195532_djx236-B8","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1111\/imr.12234","article-title":"Do we need more drugs for chronic myeloid leukemia?","volume":"263","author":"Holyoake","year":"2015","journal-title":"Immunol Rev."},{"issue":"3","key":"key\n\t\t\t\t20180510195532_djx236-B9","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1586\/era.12.10","article-title":"Mechanisms and novel approaches in overriding tyrosine kinase inhibitor resistance in chronic myeloid leukemia","volume":"12","author":"Karvela","year":"2012","journal-title":"Expert Rev Anticancer Ther."},{"issue":"2","key":"key\n\t\t\t\t20180510195532_djx236-B10","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1177\/107327480901600204","article-title":"Mechanisms of primary and secondary resistance to imatinib in chronic myeloid leukemia","volume":"16","author":"Quintas-Cardama","year":"2009","journal-title":"Cancer Control."},{"issue":"7","key":"key\n\t\t\t\t20180510195532_djx236-B11","doi-asserted-by":"crossref","first-page":"2242","DOI":"10.1182\/blood-2007-03-066936","article-title":"Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia","volume":"110","author":"O'Hare","year":"2007","journal-title":"Blood"},{"issue":"5","key":"key\n\t\t\t\t20180510195532_djx236-B12","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/j.ccr.2009.09.028","article-title":"AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance","volume":"16","author":"O'Hare","year":"2009","journal-title":"Cancer Cell."},{"issue":"22","key":"key\n\t\t\t\t20180510195532_djx236-B13","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1056\/NEJMoa1205127","article-title":"Ponatinib in refractory Philadelphia chromosome-positive leukemias","volume":"367","author":"Cortes","year":"2012","journal-title":"N Engl J Med."},{"issue":"19","key":"key\n\t\t\t\t20180510195532_djx236-B14","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1306494","article-title":"A phase 2 trial of ponatinib in Philadelphia chromosome-positive leukemias","volume":"369","author":"Cortes","year":"2013","journal-title":"N Engl J Med."},{"key":"key\n\t\t\t\t20180510195532_djx236-B15","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1182\/blood.V128.22.1119.1119","article-title":"Characterization of the genomic landscape of BCR-ABL1 kinase-independent mechanisms of resistance to ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia","volume":"128","author":"Eide","year":"2016","journal-title":"Blood."},{"issue":"10","key":"key\n\t\t\t\t20180510195532_djx236-B16","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2013-07-518381","article-title":"Ponatinib overcomes FGF2-mediated resistance in CML patients without kinase domain mutations","volume":"123","author":"Traer","year":"2014","journal-title":"Blood."},{"issue":"2","key":"key\n\t\t\t\t20180510195532_djx236-B17","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1182\/blood.V101.2.690","article-title":"BCR-ABL independence and LYN kinase overexpression in chronic myelogenous leukemia cells selected for resistance to STI571","volume":"101","author":"Donato","year":"2003","journal-title":"Blood."},{"issue":"23","key":"key\n\t\t\t\t20180510195532_djx236-B18","doi-asserted-by":"crossref","first-page":"9809","DOI":"10.1158\/0008-5472.CAN-08-1008","article-title":"Evidence that resistance to nilotinib may be due to BCR-ABL, Pgp, or Src kinase overexpression","volume":"68","author":"Mahon","year":"2008","journal-title":"Cancer Res."},{"issue":"12","key":"key\n\t\t\t\t20180510195532_djx236-B19","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.18632\/oncotarget.692","article-title":"All tyrosine kinase inhibitor-resistant chronic myelogenous cells are highly sensitive to ponatinib","volume":"3","author":"Cassuto","year":"2012","journal-title":"Oncotarget."},{"issue":"1","key":"key\n\t\t\t\t20180510195532_djx236-B20","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: A practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J Royal Stat Soc."},{"issue":"18","key":"key\n\t\t\t\t20180510195532_djx236-B21","first-page":"5716","article-title":"Bcr-Abl kinase modulates the translation regulators ribosomal protein S6 and 4E-BP1 in chronic myelogenous leukemia cells via the mammalian target of rapamycin","volume":"63","author":"Ly","year":"2003","journal-title":"Cancer Res."},{"issue":"6","key":"key\n\t\t\t\t20180510195532_djx236-B22","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1038\/leu.2011.55","article-title":"Omacetaxine may have a role in chronic myeloid leukaemia eradication through downregulation of Mcl-1 and induction of apoptosis in stem\/progenitor cells","volume":"25","author":"Allan","year":"2011","journal-title":"Leukemia."},{"issue":"4","key":"key\n\t\t\t\t20180510195532_djx236-B23","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1172\/JCI44145","article-title":"Next-generation mTOR inhibitors in clinical oncology: How pathway complexity informs therapeutic strategy","volume":"121","author":"Wander","year":"2011","journal-title":"J Clin Invest."},{"issue":"4","key":"key\n\t\t\t\t20180510195532_djx236-B24","doi-asserted-by":"crossref","first-page":"567","DOI":"10.4161\/cc.8.4.7659","article-title":"Not all substrates are treated equally: Implications for mTOR, rapamycin-resistance and cancer therapy","volume":"8","author":"Choo","year":"2009","journal-title":"Cell Cycle."},{"issue":"4","key":"key\n\t\t\t\t20180510195532_djx236-B25","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/j.cell.2006.03.035","article-title":"A pharmacological map of the PI3-K family defines a role for p110alpha in insulin signaling","volume":"125","author":"Knight","year":"2006","journal-title":"Cell."},{"issue":"7","key":"key\n\t\t\t\t20180510195532_djx236-B26","doi-asserted-by":"crossref","first-page":"1851","DOI":"10.1158\/1535-7163.MCT-08-0017","article-title":"Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase\/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity","volume":"7","author":"Maira","year":"2008","journal-title":"Mol Cancer Ther."},{"issue":"19","key":"key\n\t\t\t\t20180510195532_djx236-B27","doi-asserted-by":"crossref","first-page":"5869","DOI":"10.1016\/j.bmcl.2010.07.104","article-title":"PKI-179: An orally efficacious dual phosphatidylinositol-3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) inhibitor","volume":"20","author":"Venkatesan","year":"2010","journal-title":"Bioorg Med Chem Lett."},{"issue":"6","key":"key\n\t\t\t\t20180510195532_djx236-B28","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1021\/jm901830p","article-title":"Bis(morpholino-1,3,5-triazine) derivatives: Potent adenosine 5'-triphosphate competitive phosphatidylinositol-3-kinase\/mammalian target of rapamycin inhibitors: Discovery of compound 26 (PKI-587), a highly efficacious dual inhibitor","volume":"53","author":"Venkatesan","year":"2010","journal-title":"J Med Chem."},{"issue":"21","key":"key\n\t\t\t\t20180510195532_djx236-B29","doi-asserted-by":"crossref","first-page":"7579","DOI":"10.1021\/jm2009327","article-title":"Discovery of a potent, selective, and orally available class I phosphatidylinositol 3-kinase (PI3K)\/mammalian target of rapamycin (mTOR) kinase inhibitor (GDC-0980) for the treatment of cancer","volume":"54","author":"Sutherlin","year":"2011","journal-title":"J Med Chem."},{"issue":"12","key":"key\n\t\t\t\t20180510195532_djx236-B30","doi-asserted-by":"crossref","first-page":"2426","DOI":"10.1158\/1535-7163.MCT-11-0446","article-title":"GDC-0980 is a novel class I PI3K\/mTOR kinase inhibitor with robust activity in cancer models driven by the PI3K pathway","volume":"10","author":"Wallin","year":"2011","journal-title":"Mol Cancer Ther."},{"issue":"2","key":"key\n\t\t\t\t20180510195532_djx236-B31","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1158\/1535-7163.MCT-12-0466","article-title":"VS-5584, a novel and highly selective PI3K\/mTOR kinase inhibitor for the treatment of cancer","volume":"12","author":"Hart","year":"2013","journal-title":"Mol Cancer Ther."},{"issue":"1","key":"key\n\t\t\t\t20180510195532_djx236-B32","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1158\/0008-5472.CAN-09-1751","article-title":"AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity","volume":"70","author":"Chresta","year":"2010","journal-title":"Cancer Res."},{"issue":"6","key":"key\n\t\t\t\t20180510195532_djx236-B33","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1038\/nrm1660","article-title":"Autophagy in metazoans: Cell survival in the land of plenty","volume":"6","author":"Lum","year":"2005","journal-title":"Nat Rev Mol Cell Biol."},{"issue":"8","key":"key\n\t\t\t\t20180510195532_djx236-B34","doi-asserted-by":"crossref","first-page":"2035","DOI":"10.1182\/blood-2011-01-330621","article-title":"Kill one bird with two stones: Potential efficacy of BCR-ABL and autophagy inhibition in CML","volume":"118","author":"Helgason","year":"2011","journal-title":"Blood."},{"issue":"5","key":"key\n\t\t\t\t20180510195532_djx236-B35","doi-asserted-by":"crossref","first-page":"452","DOI":"10.4161\/auto.4451","article-title":"Dissection of the autophagosome maturation process by a novel reporter protein, tandem fluorescent-tagged LC3","volume":"3","author":"Kimura","year":"2007","journal-title":"Autophagy."},{"issue":"4","key":"key\n\t\t\t\t20180510195532_djx236-B36","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1083\/jcb.200507002","article-title":"p62\/SQSTM1 forms protein aggregates degraded by autophagy and has a protective effect on huntingtin-induced cell death","volume":"171","author":"Bjorkoy","year":"2005","journal-title":"J Cell Biol."},{"issue":"1","key":"key\n\t\t\t\t20180510195532_djx236-B37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/15548627.2015.1100356","article-title":"Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)","volume":"12","author":"Klionsky","year":"2016","journal-title":"Autophagy."},{"issue":"9","key":"key\n\t\t\t\t20180510195532_djx236-B38","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1172\/JCI33337","article-title":"Ablation of PI3K blocks BCR-ABL leukemogenesis in mice, and a dual PI3K\/mTOR inhibitor prevents expansion of human BCR-ABL+ leukemia cells","volume":"118","author":"Kharas","year":"2008","journal-title":"J Clin Invest."},{"key":"key\n\t\t\t\t20180510195532_djx236-B39","doi-asserted-by":"crossref","first-page":"e827","DOI":"10.1038\/cddis.2013.309","article-title":"PI3K\/mTOR pathway inhibitors sensitize chronic myeloid leukemia stem cells to nilotinib and restore the response of progenitors to nilotinib in the presence of stem cell factor","volume":"4","author":"Airiau","year":"2013","journal-title":"Cell Death Dis."},{"issue":"2","key":"key\n\t\t\t\t20180510195532_djx236-B40","doi-asserted-by":"crossref","DOI":"10.4161\/cbt.26725","article-title":"Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation","volume":"15","author":"Okabe","year":"2013","journal-title":"Cancer Biol Ther."},{"issue":"28","key":"key\n\t\t\t\t20180510195532_djx236-B41","doi-asserted-by":"crossref","first-page":"12469","DOI":"10.1073\/pnas.1005114107","article-title":"Critical roles for mTORC2- and rapamycin-insensitive mTORC1-complexes in growth and survival of BCR-ABL-expressing leukemic cells","volume":"107","author":"Carayol","year":"2010","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"2","key":"key\n\t\t\t\t20180510195532_djx236-B42","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1038\/nm.2091","article-title":"Effective and selective targeting of leukemia cells using a TORC1\/2 kinase inhibitor","volume":"16","author":"Janes","year":"2010","journal-title":"Nat Med."},{"issue":"2","key":"key\n\t\t\t\t20180510195532_djx236-B43","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1007\/s10637-015-0218-6","article-title":"A phase 1 study of the sachet formulation of the oral dual PI3K\/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors","volume":"33","author":"Bendell","year":"2015","journal-title":"Invest New Drugs."},{"issue":"2","key":"key\n\t\t\t\t20180510195532_djx236-B44","first-page":"713","article-title":"A phase II study of BEZ235 in patients with everolimus-resistant, advanced pancreatic neuroendocrine tumours","volume":"36","author":"Fazio","year":"2016","journal-title":"Anticancer Res."},{"issue":"20","key":"key\n\t\t\t\t20180510195532_djx236-B45","doi-asserted-by":"crossref","first-page":"4175","DOI":"10.1182\/blood-2012-11-466938","article-title":"Genomic instability may originate from imatinib-refractory chronic myeloid leukemia stem cells","volume":"121","author":"Bolton-Gillespie","year":"2013","journal-title":"Blood."},{"issue":"1","key":"key\n\t\t\t\t20180510195532_djx236-B46","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1042\/bse0550133","article-title":"Role of autophagy in cancer prevention, development and therapy","volume":"55","author":"Helgason","year":"2013","journal-title":"Essays Biochem."},{"issue":"8","key":"key\n\t\t\t\t20180510195532_djx236-B47","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.4161\/auto.29119","article-title":"Combined MTOR and autophagy inhibition: Phase I trial of hydroxychloroquine and temsirolimus in patients with advanced solid tumors and melanoma","volume":"10","author":"Rangwala","year":"2014","journal-title":"Autophagy."}],"container-title":["JNCI: Journal of the National Cancer Institute"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jnci\/article-pdf\/110\/5\/467\/24797272\/djx236.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T17:07:30Z","timestamp":1719508050000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jnci\/article\/110\/5\/467\/4643200"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,11,20]]},"references-count":47,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2017,11,20]]},"published-print":{"date-parts":[[2018,5,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jnci\/djx236","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.732146639.793581831","asserted-by":"object"}]},"ISSN":["0027-8874","1460-2105"],"issn-type":[{"value":"0027-8874","type":"print"},{"value":"1460-2105","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2018,5]]},"published":{"date-parts":[[2017,11,20]]}}}